2018년04월20일fri
로그인 | 회원가입
OFF
트위터로 보내기 싸이월드 공감
기사글확대 기사글축소 기사스크랩 이메일문의 프린트하기
OS in Relapsed/Refractory B-cell acute Lymphoblastic leukemia patients receiving Inotuzumab-ozogamicin VS Standard care in Phase3 Study
Hagop M Kantarjian, Daniel J DeAngelo, Anjali S Advani, Michaela Liedtke, Wendy Stock, Nicola Goekbuget, Susan O'Brien, Giovanni Martinelli, Kongming Wang, Tao Wang, M Luisa Paccagnella, Barbara Sleight, Erik Vandendries, Matthias Stelljes
[ 2016년 06월 14일 10시 54분 ]

Background


CD22 is expressed in most (>90%) cases of B-cell acute lymphoblastic leukemia (ALL) and is an attractive target for the treatment of B-cell malignancies. Inotuzumab ozogamicin (InO), a humanized anti-CD22 antibody conjugated to calicheamicin, has demonstrated significantly superior response vs standard care (SC) in the first 218 randomized patients with relapsed/refractory (R/R) ALL in the phase 3 INO-VATE trial.


Aims


To assess overall survival (OS) and progression free survival (PFS) of adults with R/R ALL receiving InO vs SC.


Methods


In this ongoing global, 2-arm, randomized phase 3 trial (NCT01564784), patients with R/R ALL (including ~15% of patients in each arm with Philadelphia-positive ALL) due to receive salvage (S) 1 or 2 therapy were randomized to InO (starting dose 1.8 mg/m2/cycle [0.8 mg/m2 on day 1; 0.5 mg/m2 on days 8 and 15 of a 21–28 day cycle (≤6 cycles)]) or SC (either fludarabine/cytarabine [ara-C]/granulocyte colony-stimulating factor [FLAG], ara-C plus mitoxantrone, or high-dose ara-C). Study was designed with two primary endpoints: 1) OS and 2) complete remission (CR)/CR with incomplete hematologic recovery (CRi) assessed in first 218 patients randomized (results previously presented). Overall study-wise type-I error was controlled by splitting 1-sided α to 0.0125 for each endpoint. Safety was assessed in all patients who received ≥1 dose of study drug. Per protocol, the final OS analysis was to occur upon observing ~248 events; 252 events (122 with InO and 130 with SC) were observed on March 8, 2016; data as of this date are presented.


Results


The ITT analysis population included 326 patients with both arms being well balanced for baseline stratification factors. The OS hazard ratio (HR) between InO and SC was 0.77 (97.5% CI, 0.58‒1.03) with 1-sided P=0.0203 and median OS 7.7 [95% CI, 6.0‒9.2] vs 6.7 [95% CI, 4.9‒8.3] months. The second primary objective of demonstrating a statistically significant improvement in final OS with InO vs SC was not met at prespecified significance level of 0.0104. The 2-year OS rate for InO vs SC was 23% (95% CI, 16‒30%) vs 10% (95% CI, 5‒16%). It was noted, however, that the OS departed from the proportional hazards assumption. Given this, a restricted mean survival time (RMST) analysis was applied and showed: mean OS was 13.9 months for InO vs 9.9 months for SC, a difference that met statistical significance. PFS was significantly longer with InO vs SC (HR, 0.45 [97.5% CI, 0.34‒0.61]; 1-sided P<0.0001), with median PFS 5.0 [95% CI, 3.7‒5.6] vs 1.8 [95% CI, 1.5‒2.2] months. Follow-up of previously reported endpoints, including objective response, MRD-negativity, and SCT rates were all superior in the InO arm compared to the SC arm by protocol-specified criteria. Updated safety results demonstrate a tolerability and toxicity profile consistent with that reported previously.


Conclusion

Compared with SC, InO provided evidence of longer OS and significantly prolonged PFS in adult patients with R/R ALL.

대기뉴스이거나 송고가 되지 않도록 설정됨
데일리메디 dailymedi@dailymedi.com
이기자의 다른뉴스보기
무통장입금 정보입력 입금자명 입금예정일자
(입금하실 입금자명 + 입금예정일자를 입력하세요)
[관련뉴스]
- 관련뉴스가 없습니다.
트위터로 보내기 싸이월드 공감
기사글확대 기사글축소 기사스크랩 이메일문의 프린트하기
비브라운 코리아, 신임 대표이사 스테판 소이카
김유진 교수(대구가톨릭대병원 마취통증의학과), 대한뇌신경마취학회 우창학술상
김정우 교수(원광대병원 정형외과), 대한견주관절학회 CISE 우수연구자상
허륭 교수(인천성모병원 신경외과), 대한정위기능신경외과학회 회장
남도현 교수(삼성서울병원 신경외과), 제51회 유한의학상
최진규 교수(여의도성모병원 신경외과), 대한정위기능신경외과학회 학술상
장재우 대한성형안과학회 회장 취임
조빈 교수(서울성모병원 소아청소년과), 대한혈액학회 차기 이사장
강지언 제주 연강병원장 대통령 표창
김동민 교수(조선대병원 감염내과), 보건의날 국무총리 표창
은백린 교수(前 고대구로병원장) 모친상
김형중 모두병원 원장 모친상
김현경안과 김현경 원장 모친상
정승문성형외과 정승문 원장 장모상